StoneX Issues Positive Forecast for Agilon Health (NYSE:AGL) Stock Price

Agilon Health (NYSE:AGL) had its price target lifted by research analysts at StoneX from $140.00 to $145.00 in a research note issued on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. StoneX‘s price target would indicate a potential upside of 26.35% from the company’s previous close.

Several other research firms also recently weighed in on AGL. Barclays set a $111.00 price objective on Agilon Health and gave the company an “equal weight” rating in a report on Thursday, August 6th. Citigroup raised Agilon Health from a “sell” rating to a “neutral” rating and upped their target price for the stock from $105.00 to $115.00 in a report on Monday, August 10th. Robert W. Baird set a $116.00 target price on Agilon Health in a research report on Thursday, August 6th. Wells Fargo & Company reissued an “overweight” rating and set a $146.00 price target (up from $141.00) on shares of Agilon Health in a research note on Tuesday, August 11th. Finally, Benchmark restated a “buy” rating and set a $140.00 price target (up from $95.00) on shares of Agilon Health in a report on Thursday, August 6th. Seven equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $105.54.

Agilon Health Trading Up 1.1%

Shares of AGL opened at $114.77 on Wednesday. The business’s fifty day moving average is $89.65 and its 200-day moving average is $68.07. The firm has a market cap of $1.93 billion, a price-to-earnings ratio of -20.68 and a beta of 3.10. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.13 and a current ratio of 1.13. Agilon Health has a 52-week low of $7.48 and a 52-week high of $133.04.

Agilon Health (NYSE:AGL) last issued its earnings results on Wednesday, November 4th. The company reported $1.97 EPS for the quarter, topping the consensus estimate of ($1.23) by $3.20. The firm had revenue of $1.52 billion during the quarter, compared to the consensus estimate of $1.46 billion. Agilon Health had a negative return on equity of 51.97% and a negative net margin of 1.45%. Equities analysts anticipate that Agilon Health will post -2.90 EPS for the current fiscal year.

Institutional Investors Weigh In On Agilon Health

Several institutional investors and hedge funds have recently made changes to their positions in AGL. Sterling Capital Management LLC bought a new stake in Agilon Health in the third quarter valued at approximately $33,000. Root Financial Partners LLC bought a new position in Agilon Health during the 3rd quarter worth approximately $57,000. State of Alaska Department of Revenue bought a new position in Agilon Health during the 3rd quarter worth approximately $64,000. Allworth Financial LP acquired a new position in shares of Agilon Health in the 2nd quarter worth approximately $114,000. Finally, Proficio Capital Partners LLC acquired a new position in shares of Agilon Health in the 2nd quarter worth approximately $210,000.

Agilon Health Company Profile

Agilon Health is a U.S. healthcare company that partners with primary care physicians to provide care for patients enrolled in Medicare Advantage plans. Its model is designed to help physician groups move from traditional fee-for-service care toward value-based care, in which providers are rewarded for improving patients’ health and coordinating their care. The company provides participating physician groups with clinical, operational, technology and administrative support, along with resources to manage patient populations and coordinate care across local healthcare networks.